SCHEMBL1154110

SCHEMBL1154110

C[C@@H](N(C(=O)C1(C(N)=O)CCCCC1)[C@H](C)C(O)(c1ccccc1)c1ccccc1)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 1/20 0.41
CYP2D6 P10635 4/20 0.37
CYP1A2 P05177 1/20 0.37
ALDH1A1 P00352 4/20 0.35
CYP2C19 P33261 3/20 0.35
HSD17B10 Q99714 1/20 0.35
HSD11B1 P28845 1/20 0.34
KMT2A Q03164 3/20 0.33
MAPT P10636 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
AKR1C1 Q04828 1/20 0.33
LMNA P02545 2/20 0.32
SLC6A2 P23975 1/20 0.32
MEN1 O00255 2/20 0.32
TTR P02766 1/20 0.32
OPRL1 P41146 1/20 0.32
POLB P06746 2/20 0.32
CYP2C9 P11712 1/20 0.32
KCNA5 P22460 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1152638 0.99 OPRK1 (0.42) OPRK1CYP2D6CYP1A2ALDH1A1CYP2C19
SCHEMBL1152676 0.96 OPRK1 (0.42) OPRK1CYP2D6CYP1A2ALDH1A1CYP2C19
SCHEMBL1153962 0.93 OPRK1 (0.46) OPRK1CYP2D6CYP1A2ALDH1A1CYP2C19
SCHEMBL1153133 0.89 OPRK1 (0.34) OPRK1CYP1A2CYP2C19KMT2AMEN1
SCHEMBL1153488 0.88 OPRK1 (0.40) OPRK1CYP2D6CYP1A2ALDH1A1CYP2C19
SCHEMBL1153034 0.87 OPRK1 (0.34) OPRK1
SCHEMBL1154105 0.86 OPRK1 (0.41) OPRK1CYP2D6CYP1A2ALDH1A1CYP2C19
SCHEMBL1152978 0.85 SLC6A4 (0.39) ALDH1A1KMT2ALMNASLC6A2MEN1
SCHEMBL1153302 0.85 OPRK1 (0.40) OPRK1CYP2D6CYP1A2ALDH1A1CYP2C19
SCHEMBL1153577 0.85 OPRK1 (0.34) OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943799-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-24 US disclosed
US-7842839-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-30 US disclosed
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-17 US disclosed
EP-1698617-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof CYP3A7, GRK7, CYP2A7 OPRK1 1341/4885CYP2D6 60/4885CYP1A2 21/4885
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF CYP3A7, GRK7, CYP2A7 OPRK1 1341/4885CYP2D6 60/4885CYP1A2 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.